An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Silverback Therapeutics to Participate in the H.C. Wainwright Bioconnect Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Silverback Therapeutics (SBTX), a clinical-stage biopharmaceutical company based in Seattle, has announced its participation in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022. The company focuses on developing tissue-targeted therapeutics for serious diseases utilizing its proprietary ImmunoTAC technology platform. Silverback’s CEO Laura Shawver and President Valerie Odegard will present a corporate overview available on the company's Investor Relations website starting January 10, 2022, at 7:00 AM ET.
Positive
None.
Negative
None.
SEATTLE--(BUSINESS WIRE)--
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Silverback management will participate in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022.
Laura Shawver, Ph.D., Silverback’s Chief Executive Officer, and Valerie Odegard, Ph.D., Silverback’s President and Chief Scientific Officer, will provide a corporate overview which will be available on Silverback’s Investor Relations website beginning on Monday, January 10, 2022, at 7:00 AM ET (4:00 AM PT).
About Silverback Therapeutics
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Initially, Silverback is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Silverback Therapeutics is located in Seattle, Washington. To learn more, visit www.silverbacktx.com.
What is Silverback Therapeutics' participation in the H.C. Wainwright Bioconnect Conference?
Silverback Therapeutics will participate in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022.
Who will represent Silverback Therapeutics at the conference?
Laura Shawver, CEO, and Valerie Odegard, President, will represent Silverback Therapeutics at the conference.
When will Silverback Therapeutics provide a corporate overview?
Silverback Therapeutics will provide a corporate overview starting on January 10, 2022, at 7:00 AM ET.
What is Silverback Therapeutics' focus in biopharmaceuticals?
Silverback Therapeutics focuses on developing systemically delivered, tissue-targeted therapeutics for cancer and chronic viral infections using its ImmunoTAC technology.
Where is Silverback Therapeutics located?
Silverback Therapeutics is located in Seattle, Washington.
